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Abstract
Background and aims To assess experts’ preference for sarcopenia outcomes.
Methods A discrete-choice experiment was conducted among 37 experts (medical doctors and researchers) from different 
countries around the world. In the survey, they were repetitively asked to choose which one of two hypothetical patients suf-
fering from sarcopenia deserves the most a treatment. The two hypothetical patients differed in five pre-selected sarcopenia 
outcomes: quality of life, mobility, domestic activities, fatigue and falls. A mixed logit panel model was used to estimate the 
relative importance of each attribute.
Results All sarcopenia outcomes were shown to be significant, and thus, important for experts. Overall, the most important 
sarcopenia outcome was falls (27%) followed by domestic activities and mobility (24%), quality of life (15%) and fatigue 
(10%).
Discussion and conclusion Compared to patient’s preferences, experts considered falls as a more important outcome of 
sarcopenia, while the outcomes fatigue and difficulties in domestic activities were considered as less important.
Keywords Discrete-choice experiment · Sarcopenia · Outcomes
Introduction
Sarcopenia, defined by the European Working Group on Sar-
copenia in Older People (EWGSOP2) [1] as a loss of mus-
cle strength combined with a loss of muscle mass, is now 
recognized to engender multiple health consequences, both 
at the individual as well as the societal level [2]. Within a 
patient-centered care approach, Hiligsmann et al. conducted, 
in 2019, a discrete-choice experiment (DCE) [3] among 216 
sarcopenic patients from 6 European countries to identify the 
most important outcomes for patients. Results highlighted 
decreased mobility and difficulties with domestic activities 
as the two most important sarcopenia-related outcomes for 
patients.
Besides the patients’ point of view, assessing the pref-
erences of experts (including healthcare professionals) for 
sarcopenia outcomes would be interesting, especially as dis-
cordance in preferences between patients and professionals 
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for healthcare observations have been regularly observed [4]. 
Particularly for outcomes preferences, it has been shown, 
for example, that healthcare providers and patients could be 
concordant on the importance of outcomes such as quality 
of life but discordant on mortality as a relevant outcome, the 
latter being systematically rated as much more important 
by healthcare providers than by patients [4, 5]. DCE studies 
provide an excellent opportunity to determine whether there 
is concordance of preferences between patients and health 
care providers. The preferences of healthcare professionals 
for specific outcomes may exert a relevant impact on the 
management of health resources, e.g., sarcopenic patient 
care.
This study aimed, therefore, to assess experts’ preference 
for sarcopenia outcomes through a DCE, and to compare 
experts’ preferences to patients’ preferences, which were 
identified by the previous study.
Methods
In the present study, we used the same DCE as was used 
to elicit patients’ preferences for sarcopenia outcomes [3]. 
In the DCE survey, participants were repetitively asked to 
choose which one of two hypothetical patients (Patient A 
and Patient B) suffering from sarcopenia deserves the most 
a treatment. The two hypothetical patients presented dif-
ferent levels of risk for five sarcopenia outcomes (i.e., the 
“attributes”): quality of life, mobility, domestic activities, 
fatigue and falls. More information regarding the full meth-
odology of attributes and level selections for the sarcopenia 
outcomes presented in the choice sets can be found in previ-
ous publications [3, 6]. Briefly, a literature review, an expert 
consultation, a focus group with participants suffering from 
sarcopenia and an expert meeting have been conducted to 
identify both the attributes and the levels relevant for the 
DCE. Attributes and levels included in the DCE are dis-
played in Table 1. Two versions of the questionnaire were 
randomly proposed to participants. A total of 24 choice tasks 
were designed and blocked into these 2 versions containing 
12 choice tasks each. An example of choice set is presented 
in Fig. 1. A dominance test, i.e., a choice set with one hypo-
thetical patient who has clearly better outcomes than the 
other, was added to the questionnaire to assess the reliability 
of respondents’ choices. Patients who failed the dominance 
test were excluded from the analyses. The full questionnaire 
is available on request to the corresponding author.
Sarcopenia experts involved in the present DCE were 
recruited, in 2019, among experts from the Special Interest 
Group in Sarcopenia from the European Geriatric Medicine 
Society (EUGMS). The SIG comprised 84 international 
European and non-European healthcare professionals, 
e.g., medical doctors specialized in geriatrics, nutrition or 
physical rehabilitation, as well as researchers working in 
the field of sarcopenia. Participants were invited by email 
and the DCE questionnaire was developed in an online self-
administered format using Qualtrics (Qualtrics, Provo, UT, 
USA). Data on participants’ demographics and socioeco-
nomic characteristics were collected, e.g., sex, age, work-
place, specialization and year of experience.
Data analysis was carried out using Nlogit software, ver-
sion 5.0. In line with the patients DCE, a mixed logit panel 
model was used to estimate the relative importance of each 
DCE attribute for the experts. Standard deviation signifi-
cantly different from zero was interpreted as evidence of sig-
nificant preference heterogeneity for the attributes and levels 
in the sample. The relative importance of each outcome was 
calculated by dividing the attribute-specific level range by 
the sum of all attribute level ranges.
Results
Among 84 members of the SIG sarcopenia group of the 
EUGMS, 37 (44.0%) completed the questionnaire, but 4 
participants failed the dominance test and were, therefore, 
excluded. The remaining 33 respondents were gender bal-
anced with 51.5% being female and 48.5% being male. The 
majority of the respondents were medical doctors (66.7%), 
while some researchers (24.2%) as well as Ph.D. students 
in the field of sarcopenia (9.1%) also completed the survey. 
The median professional experience of experts was 9 years 
(3–15 years). Experts were recruited from various countries 
in Europe and across the world: Belgium (n = 6), France 
(n = 3), Germany (n = 1), Italy (n = 1), Netherlands (n = 2), 
Table 1  Attributes and levels included in the DCE
Attributes Levels
Patient’s mobility Outdoor mobility without difficulties
Outdoor mobility with difficulties
Indoor mobility only
Chairbound or bedbound
Patient’s quality of life Good
Fair
Poor





Patient’s level of fatigue Not at all tired
Moderately tired
Tired very easily
Frequency of falls Never
Occasional (once in the last 6 mo)
Frequent (2 or more times in the last 6 mo)
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Poland (n = 1), Spain (n = 4), Sweden (n = 1), Switzerland 
(n = 3), Turkey (n = 5), Czech Republic (n = 1), UK (n = 1), 
Australia (n = 1), Saudi Arabia (n = 1) and USA (n = 2).
Results of the mixed logit model are reported in Table 2. 
All five pre-selected sarcopenia outcomes were statistically 
significant, and thus, important for experts. The signs of 
coefficient were as excepted, and the standard deviations 
were significant for patients’ mobility, patients’ manage-
ment of domestic activities and frequency of falls, indicating 
variability in the respondents’ preferences. Overall, the most 
important sarcopenia outcome for experts was falls (27%) 
followed by patient’s management of domestic activities and 
patient’s mobility (24%), patient’s quality of life (15%) and 
fatigue (10%).
Discussion
This DCE study highlights that experts valued falls as the 
most relevant outcome. Compared to a similar study con-
ducted with patients suffering from sarcopenia, some dif-
ferences in the relative importance of sarcopenia outcomes 
were observed. Experts considered falls as more important 
that patients did (27% versus 18%), while fatigue (10% ver-
sus 17%) and mobility (24% versus 30%) were less impor-
tant for experts. Both experts and patients seem, however, 
concordant about the level of importance of quality of life 
and the ability of managing domestic activities as outcomes 
of sarcopenia.
Different reasons could explain the differences between 
experts and patients on outcome ranking. Falls, for example, 
could have been considered more important by experts as 
they are well aware of the potential burden of falls from the 
perspective of the individual as well as from a public health 
point of view. Falls can be dramatic and have been shown 
to increase the risk of injuries, hospitalization, institution-
alization, healthcare costs, and death [7–9]. They are also 
related to a reduction of quality of life, which could partially 
explain their higher ranking. Indeed, quality of life could be 
considered as a consequence of other outcomes [10]. Falls 
may be regarded as an objective clinical outcome that could 
be measured in future studies.
Patients, on the other side, seem to be more concerned 
about outcomes that directly impact their daily life, such 
as fatigue or mobility limitations, which can restrict them-
selves with regards to their independence, social interac-
tions and which can also directly or indirectly impact other 
outcomes such as the ability to perform domestic activities 
and quality of life [11]. Fatigue was a more important out-
come for patients, but showed the lowest ranking among 
experts. Fatigue related to sarcopenia may be considered by 
clinicians as a natural consequence of sarcopenia without 
a major impact on individual health or society. When the 
five outcomes were generated from the literature review, the 
patients’ perspective and the experts’ perspective, this out-
come was not identified at all by the experts’ panel, probably 
because of the highly subjective nature of this outcome that 
is only felt by the patients themselves.
Fig. 1  Example choice set of the DCE questionnaire
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To our knowledge, this study provides the first assess-
ment of experts’ preferences on sarcopenia outcomes and 
it revealed some differences between experts and patients. 
Results of such DCE identifying the most relevant outcomes 
of sarcopenia could be useful for the choice of primary and 
secondary endpoints of future interventional studies [12]. As 
experts and patients assigned different priorities to outcomes 
of sarcopenia, it is highly important to take both perspectives 
into account.
However, some potential limitations of this study exist. 
First, only a restricted sample size of experts was included, 
which could limit the generalizability of our results. Even 
if there is no specific power size recommended for con-
ducting DCE, de Bekker-Grob [13] published a review in 
2015 that showed among a sample of 69 DCEs performed 
in Healthcare, that a mean of 100–300 respondents is often 
targeted for DCE, which is noticeably higher than our sam-
ple size. Despite a moderate sample size, we nevertheless 
tried to be as much representative as possible by including 
heterogeneous profiles of experts from different European 
and non-European countries. Second, DCEs are evaluating 
hypothetical options. It is, therefore, impossible to guarantee 
that responders will apply their choices in real life.
Conclusion
Sarcopenia experts and patients suffering from sarcopenia 
assigned different priorities to outcomes associated with 
this condition. This discordance highlights the importance 
of considering both perspectives for the choice of primary 
and secondary outcomes in future intervention trials.
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Table 2  Results from the Panel Mixed Logit Model
* P < 0.05
** P < 0.01




 Outdoor mobility without difficulties − 1.59 (− 2.53;− 0.66)** 1.11*
 Outdoor mobility with difficulties 0.81 (0.05;1.58)* 1.27**
 Indoor mobility only 0.66 (− 0.03;1.36) 0.51
 Chairbound/bedbound 0.1179 (− 0.93;1.17)
Patient’s quality of life 15%
 Good − 0.82 (− 1.37;− 0.27)** 0.39
 Fair 0.12 (− 0.25;0.49)
 Poor 0.70 (0.18;1.2)** 0.43
Patient’s management of domestic activities 24%
 Manages without difficulties − 1.61 (− 2.52;− 0.71)** 0.57
 Manages with difficulty 0.79 (0.16;1.41)*
 Unable 0.82 (0.19;1.46)* 0.84**
Patient’s level of fatigue 10%
 Not at all tired − 0.52 (− 1.01;-0.02)* 0.19
 Moderately tired − 0.03 (− 0.36;0.29)
 Tired very easily 0.54 (0.01–1.07)* 0.01
Frequency of falls 27%
 Never − 1.40 (− 2.25;− 0.56)** 0.67**
 Occasional (once in the last 6 months) 0.02 (− 0.43;0.47)
 Frequent (2 or more times in the last 6 months) 1.38 (0.58–2.18)** 0.77**
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Informed consent No informed consent was necessary (data were col-
lected using an anonymous online survey). Taking part into the survey 
was considered as a consent.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
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